Clinical Trial Update: Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial of YM-155 for refractory diffuse large B-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• YM-155

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell Refractory | Phase 2 | Status: TERMINATED